Ticker
ADAP

Price
1.08
Stock movement up
+0.04 (3.85%)
Company name
Adaptimmune Therapeutics Plc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
178.53M
Ent value
317.53M
Price/Sales
6.58
Price/Book
2.18
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-35.33%
3 year return
-54.40%
5 year return
-39.10%
10 year return
-
Last updated: 2023-06-06
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
June 1, 2023

iO Charts is a Seeking Alpha partner

Adaptimmune Therapeutics plc (NASDAQ:NASDAQ:ADAP) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ETCompany ParticipantsJuli Miller - Head-Investor RelationsAdrian Rawcliffe - Chief...
May 12, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

ADAP does not pay dividends or no data was received
Loading...
AD

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales6.58
Price to Book2.18
EV to Sales11.70
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
May 12, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
May 11, 2023

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count165.30M
EPS (TTM)-0.17
FCF per share (TTM)-0.17

Income statement

Loading...
Income statement data
Revenue (TTM)27.15M
Gross profit (TTM)27.15M
Operating income (TTM)-136.72M
Net income (TTM)-165.46M
EPS (TTM)-0.17
EPS (1y forward)-0.52

Margins

Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)-503.62%
Profit margin (TTM)-609.46%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash108.03M
Net receivables7.43M
Total current assets255.37M
Goodwill0.00
Intangible assets442.00K
Property, plant and equipment0.00
Total assets328.92M
Accounts payable4.75M
Short/Current long term debt23.08M
Total current liabilities64.50M
Total liabilities247.04M
Shareholder's equity81.88M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-141.77M
Capital expenditures (TTM)29.50M
Free cash flow (TTM)-171.26M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-202.08%
Return on Assets-50.30%
Return on Invested Capital-195.56%
Cash Return on Invested Capital-202.43%
Loading...
AD

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.05
Daily high1.12
Daily low0.99
Daily Volume2.36M
All-time high21.12
1y analyst estimate5.86
Beta2.21
EPS (TTM)-0.17
Dividend per share-
Ex-div date-
Next earnings date2 Aug 2023

Downside potential

Loading...
Downside potential data
ADAPS&P500
Current price drop from All-time high-94.89%-10.40%
Highest price drop-96.57%-56.47%
Date of highest drop15 Nov 20199 Mar 2009
Avg drop from high-71.49%-11.53%
Avg time to new high407 days13 days
Max time to new high2008 days1805 days
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
May 11, 2023

iO Charts is a Seeking Alpha partner

ADAP is swapping 1.5117 of its shares for every TCRR share. Click to read how shareholders can lock in a big gain once the deal closes.
April 21, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ADAP (Adaptimmune Therapeutics Plc) company logo
Marketcap
178.53M
Marketcap category
Small-cap
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Employees
534
Investor relations
-
SEC filings
CEO
Adrian Rawcliffe
Country
USA
City
Abingdon
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
April 18, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
April 11, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Adaptimmune is down after merging with TCR2, while TCR2 is up. Read more to see why the merger with TCRR stock looks like a smart deal for ADAP stock.
March 26, 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
March 23, 2023
Adaptimmune Therapeutics plc (NASDAQ:NASDAQ:ADAP) Q4 2022 Earnings Conference Call March 6, 2023 8:00 AM ETCompany ParticipantsJuli Miller - Head-Investor RelationsAdrian Rawcliffe - Chief...
March 6, 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
March 6, 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
March 6, 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
March 6, 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
March 3, 2023
TCR² Therapeutics has refocused its pipeline to a few specific clinical products. Read more to see why I'm bullish on TCRR stock.
February 15, 2023
Get the latest news and real-time alerts from Adaptimmune Therapeutics plc (ADAP) stock at Seeking Alpha.
January 3, 2023
Adaptimmune has been in a sea of trouble, lately. Its rolling BLA of afamicel, to be started this quarter, is its immediate lifeline. Read our analysis of ADAP stock.
December 9, 2022
iO Charts is a Seeking Alpha partnerNext page